(ENTA)—ABBV CFO Bill Chase on today’s Jefferies webcast: • Mavyret’s launch has been “stunning.” • (Duopoly) pricing stability in HCV market has been achieved. • HCV market will still be treating 300K+ patients per year a decade from now.